CN101687022A8 - Prame衍生的肽以及包括该肽的免疫原组合物 - Google Patents

Prame衍生的肽以及包括该肽的免疫原组合物 Download PDF

Info

Publication number
CN101687022A8
CN101687022A8 CN200880009876.5A CN200880009876A CN101687022A8 CN 101687022 A8 CN101687022 A8 CN 101687022A8 CN 200880009876 A CN200880009876 A CN 200880009876A CN 101687022 A8 CN101687022 A8 CN 101687022A8
Authority
CN
China
Prior art keywords
peptide
amino acid
prame
derivative
immunogenic composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN200880009876.5A
Other languages
English (en)
Other versions
CN101687022B (zh
CN101687022A (zh
Inventor
J·凯斯勒
M·格里菲恩
C·J·M·梅里芙
J·W·德里夫霍特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leiden Teaching Hospital Leiden University Medical Center
Original Assignee
Leiden Teaching Hospital Leiden University Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leiden Teaching Hospital Leiden University Medical Center filed Critical Leiden Teaching Hospital Leiden University Medical Center
Priority to CN201610596359.9A priority Critical patent/CN106220721B/zh
Publication of CN101687022A publication Critical patent/CN101687022A/zh
Publication of CN101687022A8 publication Critical patent/CN101687022A8/zh
Application granted granted Critical
Publication of CN101687022B publication Critical patent/CN101687022B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464489—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及一种长度小于100个氨基酸的肽，该肽包括源自人PRAME蛋白的氨基酸序列的至少19个连续的氨基酸，其中，所述肽包括源自人PRAME蛋白的氨基酸序列的至少一个II类HLA表位和至少一个I类HLA表位；还涉及所述肽本身以及以组合物的形式用作治疗和/或预防癌症的药物的应用。
CN200880009876.5A 2007-03-26 2008-03-26 Prame衍生的肽以及包括该肽的免疫原组合物 Expired - Fee Related CN101687022B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610596359.9A CN106220721B (zh) 2007-03-26 2008-03-26 Prame衍生的肽以及包括该肽的免疫原组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07104893.8 2007-03-26
EP07104893 2007-03-26
PCT/NL2008/050171 WO2008118017A2 (en) 2007-03-26 2008-03-26 Prame derived peptides and immunogenic compositions comprising these

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610596359.9A Division CN106220721B (zh) 2007-03-26 2008-03-26 Prame衍生的肽以及包括该肽的免疫原组合物

Publications (3)

Publication Number Publication Date
CN101687022A CN101687022A (zh) 2010-03-31
CN101687022A8 true CN101687022A8 (zh) 2016-08-24
CN101687022B CN101687022B (zh) 2016-09-07

Family

ID=38267662

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200880009876.5A Expired - Fee Related CN101687022B (zh) 2007-03-26 2008-03-26 Prame衍生的肽以及包括该肽的免疫原组合物
CN201610596359.9A Expired - Fee Related CN106220721B (zh) 2007-03-26 2008-03-26 Prame衍生的肽以及包括该肽的免疫原组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610596359.9A Expired - Fee Related CN106220721B (zh) 2007-03-26 2008-03-26 Prame衍生的肽以及包括该肽的免疫原组合物

Country Status (8)

Country Link
US (3) US8492514B2 (zh)
EP (3) EP2125005B1 (zh)
JP (2) JP5649952B2 (zh)
CN (2) CN101687022B (zh)
AU (1) AU2008230240B2 (zh)
CA (2) CA2996732C (zh)
ES (1) ES2539812T3 (zh)
WO (1) WO2008118017A2 (zh)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3018146A1 (en) * 2009-11-18 2016-05-11 MannKind Corporation Monoclonal antibodies and diagnostic uses thereof
NL2007536C2 (en) 2011-10-05 2013-04-08 Academisch Ziekenhuis Leiden Lumc Adjuvant compound.
US9758829B2 (en) 2012-06-22 2017-09-12 Htg Molecular Diagnostics, Inc. Molecular malignancy in melanocytic lesions
JP6659535B2 (ja) 2013-06-28 2020-03-04 オークランド ユニサービシーズ リミティド アミノ酸及びペプチド接合体及び接合方法
US10188712B2 (en) * 2013-07-30 2019-01-29 Biontech Ag Tumor antigens for determining cancer therapy
WO2016103192A1 (en) 2014-12-23 2016-06-30 Margaret Anne Brimble Amino acid and peptide conjugates and uses thereof
CA2986713A1 (en) 2015-05-22 2016-12-01 Memorial Sloan-Kettering Cancer Center T cell receptor-like antibodies specific for a prame peptide
EP3112375A1 (en) * 2015-07-03 2017-01-04 Ludwig-Maximilians-Universität München Antigenic peptides for the diagnosis, therapy monitoring and/or treatment of psoriasis vulgaris
CN106519019B (zh) * 2015-11-06 2018-07-03 广东香雪精准医疗技术有限公司 识别prame抗原的tcr
CN106831978B (zh) * 2015-12-04 2020-05-26 中国科学院广州生物医药与健康研究院 识别prame抗原的t细胞受体
IL298653A (en) 2015-12-11 2023-01-01 Immatics Biotechnologies Gmbh New peptides and a combination of peptides for use in immunotherapy against several types of cancer
TW201735952A (zh) 2016-02-26 2017-10-16 瑪格蕾特 安 布萊博 胺基酸及肽共軛物以及共軛過程
CN106699874B (zh) * 2016-03-29 2018-06-05 广东香雪精准医疗技术有限公司 识别prame抗原短肽的t细胞受体
CN107266552B (zh) * 2016-03-30 2022-02-08 香雪生命科学技术（广东）有限公司 源自于prame的肿瘤抗原短肽
EP3552623A1 (en) 2016-06-20 2019-10-16 ISA Pharmaceuticals B.V Formulation of a peptide vaccine
CN108203460B (zh) * 2016-12-19 2021-10-08 香雪生命科学技术（广东）有限公司 衍生自肿瘤抗原prame的短肽
CN108203459A (zh) * 2016-12-19 2018-06-26 广东香雪精准医疗技术有限公司 源自于prame的肿瘤抗原短肽
CN108264550B (zh) * 2017-01-04 2021-04-23 香雪生命科学技术（广东）有限公司 一种识别源自于prame抗原短肽的tcr
TW202325724A (zh) * 2017-01-27 2023-07-01 德商英麥提克生物技術股份有限公司 用於卵巢癌和其他癌症免疫治療的新型肽和肽組合物
NL2018803B1 (en) 2017-04-27 2018-11-05 Academisch Ziekenhuis Leiden Handelend Onder De Naam Leids Univ Medisch Centrum/ H O D N Lumc Adjuvant compounds
CN108929378B (zh) * 2017-05-22 2021-04-23 香雪生命科学技术（广东）有限公司 一种识别prame抗原的t细胞受体及编码该受体的核酸
GB201709866D0 (en) * 2017-06-20 2017-08-02 Immunocore Ltd T cell receptors
EP3661957A1 (en) * 2017-08-02 2020-06-10 IDP Discovery Pharma, S.L. Anticancer peptides
CN109400696B (zh) * 2017-08-17 2021-04-23 香雪生命科学技术（广东）有限公司 一种识别prame抗原短肽的tcr
CN117264963A (zh) * 2017-12-13 2023-12-22 艾诺奥医药品有限公司 靶向prame的癌症疫苗和其用途
CA3223357A1 (en) 2021-07-12 2023-01-19 Brigitte Elisa Anna Burm Improved substance quantification in complex mixtures
WO2024068636A1 (en) 2022-09-27 2024-04-04 Isa Pharmaceuticals B.V. Adjuvanted immunogenic peptides for intradermal administration
WO2024079311A1 (en) 2022-10-13 2024-04-18 Isa Pharmaceuticals B.V. Modified long peptides suitable for use in immunisation
WO2024149888A1 (en) 2023-01-12 2024-07-18 Isa Pharmaceuticals B.V. Improved lipopeptide quantification

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830753A (en) 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
CN1762492A (zh) 1998-05-23 2006-04-26 莱顿大学医学中心 Cd40结合分子和ctl肽在用于***的药物组合物中的用途
US20030118588A1 (en) 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
EP1118860A1 (en) * 2000-01-21 2001-07-25 Rijksuniversiteit te Leiden Methods for selecting and producing T cell peptide epitopes and vaccines incorporating said selected epitopes
FR2804117B1 (fr) 2000-01-21 2004-08-20 Bio Merieux Procede d'isolement de proteines et/ou d'acides nucleiques, complexes de particules et de proteines et/ou d'acides nucleiques, reactif et applications
WO2001090179A2 (en) * 2000-05-23 2001-11-29 Lexicon Genetics Incorporated Novel human thrombospondin-like proteins and polynucleotides encoding the same
AUPQ776100A0 (en) * 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
ES2519043T3 (es) 2000-12-08 2014-11-06 Academisch Ziekenhuis Leiden Péptidos largos de 22-45 residuos de aminoácidos que inducen y/o mejoran las respuestas inmunológicas específicas para antígenos
WO2003008537A2 (en) 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
AU2003224819A1 (en) * 2002-04-01 2003-10-20 Euro-Celtique S.A. Epitope constructs comprising antigen presenting cell targeting mechanisms
CN1691964A (zh) * 2002-09-06 2005-11-02 曼康公司 表位序列
US20080274129A1 (en) * 2003-04-18 2008-11-06 Fikes John D Hla-A2 Tumor Associated Antigen Peptides and Compositions
DE602004028468D1 (de) * 2003-06-17 2010-09-16 Mannkind Corp Haltung von immunantworten gegen mhc-klasse-i-beschränkte epitope, für prophylaktische oder therapeutische zwecke
US7340702B2 (en) * 2003-07-23 2008-03-04 Cadence Design Systems, Inc. Method and apparatus for induction proof
CA2571168A1 (en) 2004-06-17 2006-01-26 Mannkind Corporation Mhc i-binding ssx-241-49 variants
NZ564359A (en) * 2005-06-17 2011-09-30 Mannkind Corp Analogs of pepetides corresponding to class I MHC-restricted T cell epitopes
KR20080026181A (ko) * 2005-06-17 2008-03-24 맨카인드 코포레이션 암세포 및 종양 기질에 발현된 우성 및 준우성 에피토프에대한 다가 면역반응을 유발하기 위한 방법 및 조성물

Also Published As

Publication number Publication date
AU2008230240A1 (en) 2008-10-02
CN106220721B (zh) 2020-04-07
US10450356B2 (en) 2019-10-22
CN106220721A (zh) 2016-12-14
EP2125005B1 (en) 2015-04-08
EP2125005A2 (en) 2009-12-02
CA2996732A1 (en) 2008-10-02
JP2014240407A (ja) 2014-12-25
CA2996732C (en) 2020-10-27
CA2681132C (en) 2018-05-01
EP2462947A1 (en) 2012-06-13
US20100120683A1 (en) 2010-05-13
US20160333065A1 (en) 2016-11-17
WO2008118017A3 (en) 2008-12-31
WO2008118017A2 (en) 2008-10-02
CN101687022B (zh) 2016-09-07
EP3533461A3 (en) 2019-12-18
US9441025B2 (en) 2016-09-13
JP2010522748A (ja) 2010-07-08
US20140348862A1 (en) 2014-11-27
CA2681132A1 (en) 2008-10-02
EP2462947B1 (en) 2019-03-13
JP5649952B2 (ja) 2015-01-07
AU2008230240B2 (en) 2012-09-13
ES2539812T3 (es) 2015-07-06
JP5985551B2 (ja) 2016-09-06
CN101687022A (zh) 2010-03-31
EP3533461A2 (en) 2019-09-04
US8492514B2 (en) 2013-07-23

Similar Documents

Publication Publication Date Title
CN101687022A8 (zh) Prame衍生的肽以及包括该肽的免疫原组合物
CY1123901T1 (el) Φαρμακευτικη συνθεση και χορηγησεις αυτης
AR119682A2 (es) Composiciones inmunogénicas de antígenos de staphylococcus aureus
WO2018190719A3 (en) Anti-sirp alpha antibodies
EP3216462A3 (en) Stable antibody containing compositions
WO2007054279A3 (en) Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions
WO2006105112A3 (en) Amino acid-containing composition for preventing or remedying in the skeletal muscle of aged people
CY1119968T1 (el) Συνθεσεις καινοτομων καλλυντικων και/ή φαρμακευτικων προϊοντων και χρησεις αυτων
EP2567707A3 (en) Composition of tumour-associated peptides and related anti-cancer vaccine
EP2383285A3 (en) Peptide Sequences and Compositions
SI1954308T1 (sl) Stabilizatorji za liofilizirana cepiva
CY1116700T1 (el) Παρασκευη συνθετικου χολικου οξεος
WO2008036932A3 (en) Compositions and methods comprising boswellia species
ATE461214T1 (de) Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
EP3165556A3 (en) Protein-containing adhesives, and manufacture and use thereof
EP3029066A3 (en) Antibodies with modified isoelectric points
BRPI0314373B8 (pt) produto imunogênico estável para a indução de anticorpos contra uma ou várias proteínas antigênicas em um indivíduo, composições farmacêutica, imunogênica e de vacina e processo de preparação de um produto imunogênico
NZ714273A (en) Pharmaceutical composition comprising the combination of a biocompatible nanoparticle and a compound of interest, preparation and uses thereof
EP2468772A3 (en) Antibodies to EGFL7 and methods for their use
AR100768A1 (es) Método para disminuir la inmunogenicidad de proteínas y péptidos
WO2007059931A8 (en) New adjuvants on the basis of bisacyloxypropylcysteine conjugates and derivatives and their uses in pharmaceutical compositions
EA200600403A1 (ru) Препараты кладрибина для улучшенной пероральной доставки и доставки через слизистые оболочки
MX2017006813A (es) Composicion farmaceutica, preparacion y usos de la misma.
NZ594198A (en) Neil3 peptides and vaccines including the same
MX2021010595A (es) Composicion farmaceutica, preparacion y usos de la misma.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CI01 Publication of corrected invention patent application

Correction item: Third inventor

Correct: C - J - M - Meilifu

False: Melief Cornelis Johannes Maria

Number: 13

Volume: 26

CI02 Correction of invention patent application

Correction item: Third inventor

Correct: C - J - M - Meilifu

False: Melief Cornelis Johannes Maria

Number: 13

Page: The title page

Volume: 26

ERR Gazette correction
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160907